Metformin outperforms glipizide in preventing CVD events in diabetes

01/2/2013 | Modern Medicine

Long-term metformin treatment was associated with fewer cardiovascular events than glipizide therapy in type 2 diabetes patients with a history of coronary artery disease, according to a study in Diabetes Care. Data on 304 patients showed 35.1% of glipizide-treated patients experienced cardiovascular events at five years, compared with 25% of metformin-treated patients.

View Full Article in:

Modern Medicine

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX